Globus Medical (NYSE:GMED) Given New $100.00 Price Target at Needham & Company LLC

Globus Medical (NYSE:GMED) had its price target reduced by Needham & Company LLC from $117.00 to $100.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the medical device company’s stock.

Several other equities analysts also recently commented on the stock. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a report on Friday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. Truist Financial decreased their price target on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. BMO Capital Markets downgraded Globus Medical from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $94.00 to $78.00 in a research report on Friday. Finally, Royal Bank Of Canada dropped their price target on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $96.92.

Globus Medical Stock Down 13.2%

GMED stock traded down $10.77 during trading on Friday, reaching $70.67. The company’s stock had a trading volume of 9,272,194 shares, compared to its average volume of 1,321,886. The company’s fifty day moving average is $77.20 and its 200-day moving average is $83.18. The company has a market capitalization of $9.49 billion, a P/E ratio of 17.36, a price-to-earnings-growth ratio of 1.28 and a beta of 0.98. Globus Medical has a 1 year low of $70.39 and a 1 year high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.20 by $0.03. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The business had revenue of $763.72 million for the quarter, compared to the consensus estimate of $792.39 million. During the same period in the previous year, the business earned $1.18 earnings per share. The business’s revenue was down .7% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Analysts anticipate that Globus Medical will post 4.99 earnings per share for the current year.

Insiders Place Their Bets

In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director owned 25,000 shares in the company, valued at $2,176,000. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ann Rhoads sold 5,000 shares of the stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the sale, the director directly owned 35,384 shares in the company, valued at approximately $3,007,640. This represents a 12.38% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 60,000 shares of company stock valued at $4,838,400 over the last three months. 18.38% of the stock is owned by company insiders.

Hedge Funds Weigh In On Globus Medical

Several hedge funds have recently bought and sold shares of GMED. Elevation Wealth Partners LLC lifted its position in shares of Globus Medical by 2,178.6% during the second quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock worth $25,000 after purchasing an additional 305 shares during the last quarter. Continuum Advisory LLC purchased a new stake in shares of Globus Medical in the second quarter valued at approximately $25,000. Root Financial Partners LLC bought a new position in Globus Medical in the third quarter worth approximately $29,000. Heritage Family Offices LLP purchased a new stake in shares of Globus Medical in the 3rd quarter worth $31,000. Finally, Jacobi Capital Management LLC purchased a new position in shares of Globus Medical during the third quarter valued at $40,000. Institutional investors own 95.16% of the company’s stock.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.